Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
Add more filters










Publication year range
1.
Acta Physiol (Oxf) ; 223(4): e13067, 2018 08.
Article in English | MEDLINE | ID: mdl-29575758

ABSTRACT

AIM: Selenoprotein T (SelT or SELENOT) is a novel thioredoxin-like enzyme whose genetic ablation in mice results in early embryonic lethality. SelT exerts an essential cytoprotective action during development and after injury through its redox-active catalytic site. This study aimed to determine the expression and regulation of SelT in the mammalian heart in normal and pathological conditions and to evaluate the cardioprotective effect of a SelT-derived peptide, SelT43-52(PSELT) encompassing the redox motif which is key to its function, against ischaemia/reperfusion(I/R) injury. METHODS: We used the isolated Langendorff rat heart model and different analyses by immunohistochemistry, Western blot and ELISA. RESULTS: We found that SelT expression is very abundant in embryo but is undetectable in adult heart. However, SelT expression was tremendously increased after I/R. PSELT (5 nmol/L) was able to induce pharmacological post-conditioning cardioprotection as evidenced by a significant recovery of contractility (dLVP) and reduction of infarct size (IS), without changes in cardiac contracture (LVEDP). In contrast, a control peptide lacking the redox site did not confer cardioprotection. Immunoblot analysis showed that PSELT-dependent cardioprotection is accompanied by a significant increase in phosphorylated Akt, Erk-1/2 and Gsk3α-ß, and a decrement of p38MAPK. PSELT inhibited the pro-apoptotic factors Bax, caspase 3 and cytochrome c and stimulated the anti-apoptotic factor Bcl-2. Furthermore, PSELT significantly reduced several markers of I/R-induced oxidative and nitrosative stress. CONCLUSION: These results unravel the role of SelT as a cardiac modulator and identify PSELT as an effective pharmacological post-conditioning agent able to protect the heart after ischaemic injury.


Subject(s)
Antioxidants/pharmacology , Apoptosis/drug effects , Myocardial Infarction/prevention & control , Myocardial Reperfusion Injury/prevention & control , Myocytes, Cardiac/drug effects , Oxidative Stress/drug effects , Peptide Fragments/pharmacology , Selenoproteins/pharmacology , Thioredoxin-Disulfide Reductase/pharmacology , Animals , Antioxidants/metabolism , Apoptosis Regulatory Proteins/metabolism , Disease Models, Animal , Isolated Heart Preparation , Male , Myocardial Contraction/drug effects , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocardial Reperfusion Injury/physiopathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Nitrosative Stress/drug effects , Peptide Fragments/metabolism , Rats, Wistar , Selenoproteins/metabolism , Signal Transduction/drug effects , Thioredoxin-Disulfide Reductase/metabolism , Ventricular Function, Left/drug effects
2.
Article in English | MEDLINE | ID: mdl-29097256

ABSTRACT

Parkinson's disease (PD) is a progressive degenerative disorder that leads to disabling motor symptoms and a wide variety of neuropsychiatric symptoms. Apathy is the most common psychiatric disorder in the early stages of untreated PD and can be defined as a hypodopaminergic syndrome, which also includes anxiety and depression. Apathy is also considered the core feature of the parkinsonian triad (apathy, anxiety and depression) of behavioural non-motor signs, including a motivational deficit. Moreover, apathy is recognised as a distinct chronic neuropsychiatric behavioural disorder based on specific diagnostic criteria. Given the prevalence of apathy in approximately 40% of the general Parkinson's disease population, this appears to be a contributing factor to dementia in PD; also, apathy symptoms are factors that potentially contribute to morbidity, leading to a major impairment of health-related quality of life, thus stressing the importance of understanding the pathophysiology of this disease. Several studies have clearly established a prominent role for DA-mediated signals in PD apathy. However, synergistic interaction between dopaminergic impairment resulting from the neurodegenerative process and deep brain stimulation of the subthalamic nucleus may cause or exacerbate apathy. Furthermore, serotoninergic mechanism signalling is also likely to be of importance in this pathophysiology.


Subject(s)
Brain/physiopathology , Motivation/physiology , Parkinson Disease/physiopathology , Parkinson Disease/psychology , Animals , Humans , Parkinson Disease/diagnosis , Parkinson Disease/epidemiology
3.
J Neuroendocrinol ; 29(12)2017 12.
Article in English | MEDLINE | ID: mdl-29044774

ABSTRACT

Over the years, advances in immunohistochemistry techniques have been a critical step in detecting and mapping neuromodulatory substances in the central nervous system. The better quality and specificity of primary antibodies, new staining procedures and the spectacular development of imaging technologies have allowed such progress. Very recently, new methods permitting tissue transparency have been successfully used on brain tissues. In the present study, we combined whole-mount immunostaining for tyrosine hydroxylase (TH), oxytocin (OXT) and arginine vasopressin (AVP), with the iDISCO+ clearing method, light-sheet microscopy and semi-automated counting of three-dimensionally-labelled neurones to obtain a (3D) distribution of these neuronal populations in a 5-day postnatal (P5) mouse brain. Segmentation procedure and 3D reconstruction allowed us, with high resolution, to map TH staining of the various catecholaminergic cell groups and their ascending and descending fibre pathways. We show that TH pathways are present in the whole P5 mouse brain, similar to that observed in the adult rat brain. We also provide new information on the postnatal distribution of OXT and AVP immunoreactive cells in the mouse hypothalamus, and show that, compared to AVP neurones, OXT neurones in the supraoptic (SON) and paraventricular (PVN) nuclei are not yet mature in the early postnatal period. 3D semi-automatic quantitative analysis of the PVN reveals that OXT cell bodies are more numerous than AVP neurones, although their immunoreactive soma have a volume half smaller. More AVP nerve fibres compared to OXT were observed in the PVN and the retrochiasmatic area. In conclusion, the results of the present study demonstrate the utility and the potency of imaging large brain tissues with clearing procedures coupled to novel 3D imaging technologies to study, localise and quantify neurotransmitter substances involved in brain and neuroendocrine functions.


Subject(s)
Brain/cytology , Neurons/cytology , Oxytocin/analysis , Tyrosine 3-Monooxygenase/analysis , Vasopressins/analysis , Animals , Brain/metabolism , Female , Imaging, Three-Dimensional , Immunohistochemistry , Male , Mice, Inbred C57BL , Neurons/metabolism
4.
J Neuroendocrinol ; 29(3)2017 03.
Article in English | MEDLINE | ID: mdl-28166374

ABSTRACT

EM66 is a conserved 66-amino acid peptide derived from secretogranin II (SgII), a member of the granin protein family. EM66 is widely distributed in secretory granules of endocrine and neuroendocrine cells, as well as in hypothalamic neurones. Although EM66 is abundant in the hypothalamus, its physiological function remains to be determined. The present study aimed to investigate a possible involvement of EM66 in the hypothalamic regulation of feeding behaviour. We show that i.c.v. administration of EM66 induces a drastic dose-dependent inhibition of food intake in mice deprived of food for 18 hours, which is associated with an increase of hypothalamic pro-opiomelanocortin (POMC) and melanocortin-3 receptor mRNA levels and c-Fos immunoreactivity in the POMC neurones of the arcuate nucleus. By contrast, i.c.v. injection of EM66 does not alter the hypothalamic expression of neuropeptide Y (NPY), or that of its Y1 and Y5 receptors. A 3-month high-fat diet (HFD) leads to an important decrease of POMC and SgII mRNA levels in the hypothalamus, whereas NPY gene expression is not affected. Finally, we show that a 48 hours of fasting in HFD mice decreases the expression of POMC and SgII mRNA, which is not observed in mice fed a standard chow. Taken together, the present findings support the view that EM66 is a novel anorexigenic neuropeptide regulating hypothalamic feeding behaviour, at least in part, by activating the POMC neurones of the arcuate nucleus.


Subject(s)
Appetite Regulation/drug effects , Feeding Behavior/drug effects , Hypothalamus/drug effects , Peptide Fragments/pharmacology , Secretogranin II/pharmacology , Animals , Caloric Restriction , Food Preferences/drug effects , Hypothalamus/metabolism , Infusions, Intraventricular , Male , Mice , Mice, Inbred C57BL , Peptide Fragments/administration & dosage , Secretogranin II/administration & dosage , Secretogranin II/chemistry
5.
Cancer Lett ; 352(2): 236-44, 2014 Oct 01.
Article in English | MEDLINE | ID: mdl-25016061

ABSTRACT

Pheochromocytomas and paragangliomas are rare neuroendocrine tumors which develop from chromaffin cells of the adrenal medulla and extra-adrenal sites, leading to excess catecholamine release and hypertension. Many of the tumors are characterized by a high vascularity, suggesting the possible implementation of anti-angiogenic therapies for patients. Here, the efficacy of the tyrosine kinase inhibitors sunitinib and sorafenib was investigated in vivo and in vitro. Oral treatment with either sunitinib or sorafenib (40mg/kg/day) for 14days induced a marked reduction in the volume and weight of PC12 pheochromocytoma cell tumor xenografts in mice. Assessment of tumoral neo-angiogenesis, assessed by morphometric analysis of the vascular network after CD31 immunolabeling, showed that both sunitinib and sorafenib reduced the microvessel area (-85% and -80%, respectively) and length (-80% and -78%, respectively) in treated compared to control tumors. In addition, the number of vessel nodes was significantly lower in treated tumors (-95% and -84%, respectively). Furthermore, cleaved caspase 3 immunolabeling revealed a marked increase in the number of apoptotic cells in tumors from treated animals. Sunitinib and sorafenib could exert a direct effect on PC12 cell viability in vitro. While sunitinib induced a rapid (4h) and pronounced (5-fold) increase in caspase-3/7-dependent apoptosis, sorafenib seems to exert its cytotoxic activity through a different mechanism. Altogether, our data demonstrate that sunitinib and sorafenib have the ability to impair pheochromocytoma development by inhibiting angiogenesis and reducing tumor cell viability. These results strongly suggest that both sunitinib and sorafenib could represent valuable therapeutic tools for pheochromocytoma.


Subject(s)
Adrenal Gland Neoplasms/drug therapy , Angiogenesis Inhibitors/pharmacology , Indoles/pharmacology , Niacinamide/analogs & derivatives , Phenylurea Compounds/pharmacology , Pheochromocytoma/drug therapy , Protein Kinase Inhibitors/pharmacology , Pyrroles/pharmacology , Administration, Oral , Adrenal Gland Neoplasms/blood supply , Adrenal Gland Neoplasms/enzymology , Adrenal Gland Neoplasms/pathology , Angiogenesis Inhibitors/administration & dosage , Animals , Apoptosis/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Heterografts , Indoles/administration & dosage , Male , Mice , Mice, Nude , Neoplasm Transplantation , Neovascularization, Pathologic , Niacinamide/administration & dosage , Niacinamide/pharmacology , PC12 Cells , Phenylurea Compounds/administration & dosage , Pheochromocytoma/blood supply , Pheochromocytoma/enzymology , Pheochromocytoma/pathology , Protein Kinase Inhibitors/administration & dosage , Pyrroles/administration & dosage , Rats , Sorafenib , Sunitinib , Time Factors , Tumor Burden/drug effects
6.
J Mol Endocrinol ; 48(2): 115-27, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22217803

ABSTRACT

We have previously demonstrated that measurement of tissue concentrations of the secretogranin II (SgII or SCG2 as listed in the HUGO database)-derived peptide EM66 may help to discriminate between benign and malignant pheochromocytomas and that EM66 represents a sensitive plasma marker of pheochromocytomas. Here, we investigated the gene expression and protein production of SgII in 13 normal adrenal glands, and 35 benign and 16 malignant pheochromocytomas with the goal to examine the molecular mechanisms leading to the marked variations in the expression of EM66 in tumoral chromaffin tissue. EM66 peptide levels were 16-fold higher in benign than in malignant pheochromocytomas and had an area under the receiver-operating characteristic curve of 0.95 for the distinction of benign and malignant tumors. Q-PCR experiments indicated that the SgII gene was significantly underexpressed in malignant tumors compared with benign tumors. Western blot analysis using antisera directed against SgII and SgII-derived fragments revealed lower SgII protein and SgII-processing products in malignant tumors. Western blot also showed that low p-cAMP-responsive element-binding (CREB) concentrations seemed to be associated with the malignant status. In addition, the prohormone convertase PC1 and PC2 genes and proteins were overexpressed in benign pheochromocytomas compared with malignant pheochromocytomas. Low concentrations of EM66 found in malignant tumors are associated with reduced expression and production of SgII and SgII-derived peptides that could be ascribed to a decrease in SgII gene transcription, probably linked to p-CREB down-regulation, and to lower PC levels. These findings highlight the mechanisms leading to lower concentrations of EM66 in malignant pheochromocytoma and strengthen the notion that this peptide is a suitable marker of this neuroendocrine tumor.


Subject(s)
Adrenal Gland Neoplasms/metabolism , Biomarkers, Tumor/metabolism , Peptide Fragments/metabolism , Pheochromocytoma/metabolism , Secretogranin II/metabolism , Adolescent , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/pathology , Adrenal Glands/pathology , Adrenal Glands/physiology , Adult , Aged , Biomarkers, Tumor/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Peptide Fragments/genetics , Pheochromocytoma/genetics , Pheochromocytoma/pathology , Proprotein Convertase 1/genetics , Proprotein Convertase 1/metabolism , Proprotein Convertase 2/genetics , Proprotein Convertase 2/metabolism , Secretogranin II/genetics , Young Adult
7.
J Neuroendocrinol ; 23(8): 711-24, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21564351

ABSTRACT

Epidemiological studies suggest that maternal undernutrition sensitises to the development of chronic adult diseases, such as type 2 diabetes, hypertension and obesity. Although the physiological mechanisms involved in this 'perinatal programming' remain largely unknown, alterations of stress neuroendocrine systems such as the hypothalamic-pituitary-adrenal (HPA) and sympathoadrenal axes might play a crucial role. Despite recent reports showing that maternal perinatal undernutrition disturbs chromaffin cells organisation and activity in male rats at weaning, its long-term effects on adrenal medulla in adult animals are unknown. Using a rat model of maternal perinatal 50% food restriction (FR50) from the second week of gestation until weaning, histochemistry approaches revealed alterations in noradrenergic chromaffin cells aggregation and in cholinergic innervation in the adrenal medulla of 8-month-old FR50 rats. Electron microscopy showed that chromaffin cell granules exhibited ultrastructural changes in FR50 rats. These morphological changes were associated with reduced circulating levels and excretion of catecholamines. By contrast, catecholamine plasma levels were significantly increased after a 16 or 72 h of fasting, indicating that the responsiveness of the sympathoadrenal system to food deprivation was accentuated in FR50 adult rats. Among 384 pituitary adenylate cyclase-activating polypeptide-sensitive genes, we identified 129 genes (33.6%) that were under expressed (ratio < 0.7) in FR50 animals. A large number of these genes are involved in cytoskeleton remodelling and vesicle trafficking. Taken together, our results show that maternal perinatal undernutrition programmes adrenomedullary function and gene expression in adult male rats. Because catecholamines contribute to metabolic homeostasis, as well as arterial blood pressure regulation, the alterations observed in the adrenal medulla of adult male FR50 rats may participate in the programming of chronic adult diseases.


Subject(s)
Adrenal Medulla/anatomy & histology , Adrenal Medulla/physiology , Gene Expression , Malnutrition/physiopathology , Prenatal Exposure Delayed Effects/physiopathology , Acetylcholinesterase/metabolism , Animals , Animals, Newborn/physiology , Body Weight , Female , Food Deprivation/physiology , Humans , Hypothalamo-Hypophyseal System/physiology , Male , Pituitary-Adrenal System/physiology , Pregnancy , Rats , Rats, Wistar , Weaning
8.
Horm Metab Res ; 40(6): 386-90, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18401834

ABSTRACT

Numerous data show that malnutrition during early life programs chronic diseases in adulthood. Many of these disorders may result from alterations in the development of neuroendocrine systems, such as the hypothalamo-pituitary-adrenal axis and the sympathoadrenal system. We have previously reported that maternal 50% food restriction during late pregnancy and lactation reduces adrenal weight and impairs chromaffin cell differentiation in male rats at weaning. In addition, maternal undernutrition modifies the expression of several genes involved in proliferation and apoptosis. This study therefore investigated the impact of maternal food restriction on adrenal cell growth in the late postnatal rat. Histological analysis showed that the number of proliferating chromaffin cells assessed by nuclear labelling with BrdU was reduced by 45%, whereas the level of apoptosis visualised by caspase-3 immunoreactivity was increased by 340% in adrenal medulla of offspring from undernourished mothers. In contrast, maternal food restriction did not affect proliferation and apoptosis in cortical cells of rats. These developmental changes were associated with overexpression of TGFbeta2. These data show that perinatal undernutrition impairs the balance between chromaffin cell proliferation and apoptosis. These modifications may lead to "malprogramming" of adrenal medulla development, which could contribute to the pathogenesis of chronic diseases in adulthood.


Subject(s)
Adrenal Medulla/cytology , Apoptosis/physiology , Chromaffin Cells/cytology , Malnutrition/physiopathology , Prenatal Exposure Delayed Effects , Adrenal Medulla/physiology , Animals , Animals, Newborn , Cell Proliferation , Chromaffin Cells/physiology , Female , Hypothalamo-Hypophyseal System/cytology , Hypothalamo-Hypophyseal System/growth & development , Male , Malnutrition/pathology , Pituitary-Adrenal System/cytology , Pituitary-Adrenal System/growth & development , Pregnancy , Rats , Rats, Wistar
9.
Acta Physiol (Oxf) ; 192(2): 309-24, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18005393

ABSTRACT

Chromogranins/secretogranins or granins are a class of acidic, secretory proteins that occur in endocrine, neuroendocrine, and neuronal cells. Granins are the precursors of several bioactive peptides and may be involved in secretory granule formation and neurotransmitter/hormone release. Characterization and analysis of chromogranin A (CgA), chromogranin B (CgB), and secretogranin II (SgII) in distant vertebrate species confirmed that CgA and CgB belong to related monophyletic groups, probably evolving from a common ancestral precursor, while SgII sequences constitute a distinct monophyletic group. In particular, selective sequences within these proteins, bounded by potential processing sites, have been remarkably conserved during evolution. Peptides named vasostatin, secretolytin and secretoneurin, which occur in these regions, have been shown to exert various biological activities. These conserved domains may also be involved in the formation of secretory granules in different vertebrates. Other peptides such as catestatin and pancreastatin may have appeared late during evolution. The function of granins as propeptide precursors and granulogenic factors is discussed in the light of recent data obtained in various model species and using knockout mice strains.


Subject(s)
Chromogranins/genetics , Evolution, Molecular , Secretogranin II/genetics , Vertebrates/metabolism , Amino Acid Sequence , Animals , Base Sequence , Chromogranins/analysis , Chromogranins/metabolism , Humans , Molecular Sequence Data , Neurosecretory Systems/chemistry , Neurosecretory Systems/metabolism , Secretogranin II/analysis , Secretogranin II/metabolism , Secretory Vesicles/chemistry , Secretory Vesicles/metabolism , Sequence Alignment
10.
FEBS Lett ; 581(17): 3149-56, 2007 Jul 10.
Article in English | MEDLINE | ID: mdl-17572408

ABSTRACT

We have identified a novel vertebrate-specific gene by applying a Differential Display method on two distinct subtypes of pituitary melanotropes showing divergent secretory phenotypes of hypo- and hypersecretion. A paralogue of this gene was also identified. The existence of a long coiled-coil domain and a C-terminal transmembrane domain in the sequences, together with the Golgi distribution of the proteins in transfected cells, suggest that they can be considered as new members of the golgin family of proteins. Both genes were primarily expressed in (neuro)endocrine tissues in vertebrates thus supporting a role for these proteins in the regulated secretory pathway.


Subject(s)
Melanotrophs/metabolism , Membrane Proteins/genetics , Neurosecretory Systems/metabolism , Amino Acid Sequence , Animals , Cells, Cultured , Cloning, Molecular , Gene Expression Profiling , Humans , Membrane Proteins/metabolism , Molecular Sequence Data , Protein Structure, Tertiary/genetics , Rana ridibunda , Rats , Rats, Wistar , Sequence Homology, Amino Acid , Tissue Distribution
11.
Gen Comp Endocrinol ; 147(2): 222-30, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16480985

ABSTRACT

The frog intermediate lobe comprises two functionally distinct cell subtypes, referred to as secretory and storage melanotropes, which differ in their ultrastructure, secretory, and synthetic rates, and display dissimilar responses to hypothalamic regulatory factors. All these differences make melanotrope subtypes an excellent model to analyze the expression and regulation of genes involved in the control and maintenance of the secretory state of endocrine cells. However, quantification of the expression levels of genes involved in the secretory process requires the characterization of a gene whose expression remains constant irrespective of the secretory state of the cells. In this study, we have cloned the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene from frog pituitary and have evaluated its suitability as internal standard in gene expression studies in melanotropes. A semiquantitative RT-PCR system developed to this end revealed that secretory melanotropes and storage melanotropes possess similar expression levels of GAPDH, whereas, as expected, secretory melanotropes showed higher levels of POMC transcripts than storage cells. Furthermore, we found that the expression of the convertase PC1, an intracellular protease involved in POMC processing, parallels that of POMC, thus suggesting that the higher secretory rate of the POMC-derived peptide alpha-MSH exhibited by secretory melanotropes is supported by their higher PC1 expression levels. In addition, we have shown that both POMC and PC1 mRNAs are up-regulated by the hypothalamic factor TRH in melanotrope cell cultures. In contrast, the inhibitory factor NPY reduced the expression level of the convertase but did not modify that of POMC. Taken together, these results demonstrate that PC1 expression is regulated in melanotropes by both stimulatory (TRH) and inhibitory (NPY) hypothalamic signals, in a manner which essentially parallels that observed for the precursor POMC.


Subject(s)
Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Pro-Opiomelanocortin/metabolism , Proprotein Convertase 1/metabolism , Rana ridibunda/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Amino Acid Sequence , Animals , Base Sequence , Gene Expression Profiling , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Melanocyte-Stimulating Hormones/metabolism , Molecular Sequence Data , Neuropeptide Y/metabolism , Pro-Opiomelanocortin/genetics , Sequence Homology, Amino Acid , Thyrotropin-Releasing Hormone/metabolism
12.
Endocrinology ; 147(3): 1408-18, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16357044

ABSTRACT

Chromogranin A (CgA) and secretogranin II (SgII) are neuroendocrine secretory proteins that participate in regulation of the secretory pathway and also serve as precursors of biologically active peptides. To investigate whether there is a relationship between the expression, distribution, and processing of CgA and SgII and the degree of secretory activity, we employed two melanotrope subpopulations of the pituitary intermediate lobe that exhibit opposite secretory phenotypes. Thus, although one of the melanotrope subtypes shows high secretory activity, the other exhibits characteristics of a hormone storage phenotype. Our data show that SgII expression levels were higher in secretory melanotropes, whereas CgA expression showed similar rates in both cell subsets. The use of various antibodies revealed the presence of the unprocessed proteins as well as three CgA-derived peptides (67, 45, and 30 kDa) and six SgII-derived peptides (81, 66, 55, 37, 32, and 30 kDa) in both subpopulations. However, the smallest molecular forms of both granins predominated in secretory melanotropes, whereas the largest SgII- and CgA-immunoreactive peptides were more abundant in storage melanotropes, which is suggestive of a more extensive processing of granins in the secretory subset. Confocal microscopy studies showed that CgA immunoreactivity was higher in storage cells, but SgII immunoreactivity was higher in secretory melanotropes. Taken together, our results indicate that SgII and CgA are differentially regulated in melanotrope subpopulations. Thus, SgII expression is strongly related to the secretory activity of melanotrope cells, whereas CgA expression may not be related to secretory rate, but, rather, to hormone storage in this endocrine cell type.


Subject(s)
Chromogranins/biosynthesis , Endocrine System/metabolism , Gene Expression Regulation , Animals , Blotting, Western , Chromogranin A , Chromogranins/chemistry , Chromogranins/metabolism , Densitometry , Endocrine System/cytology , Gene Expression , Humans , Immunohistochemistry , Microscopy, Confocal , Models, Statistical , Peptides/chemistry , Phenotype , Pituitary Gland/metabolism , RNA/metabolism , RNA, Messenger/metabolism , Ranidae , Reverse Transcriptase Polymerase Chain Reaction
13.
J Neuroendocrinol ; 17(6): 372-8, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15929742

ABSTRACT

The neuroendocrine protein secretogranin II is the precursor of several neuropeptides, including secretoneurin and a novel 66-amino acid peptide, EM66, the sequence of which has been highly conserved across the vertebrae phylum. The presence of EM66 has been detected in the adult and fetal human adrenal gland, as well as the rat pituitary and adrenal glands. The present study aimed to explore a possible neuroendocrine role of EM66 by analysing its occurrence and distribution within the jerboa hypothalamus, and its potential implication in the control of feeding behaviour. High-performance liquid chromatography analysis of jerboa hypothalamic extracts combined with a radioimmunoassay of EM66 revealed a single peak of immunoreactive material exhibiting the same retention time as recombinant EM66. Immunocytochemical labelling showed that EM66-producing neurones are widely distributed in several hypothalamic regions, including the preoptic area, the suprachiasmatic, supraoptic, parvocellular paraventricular and arcuate nuclei, and the lateral hypothalamus. Food deprivation for 5 days induced a significant increase in the number of EM66-containing neurones within the arcuate nucleus (105% increase) and the parvocellular aspect of the paraventricular nucleus (115% increase), suggesting that EM66 could be involved in the control of feeding behaviour and/or the response to stress associated with fasting. Altogether, these data reveal the physiological plasticity of the EM66 system in the hypothalamus and implicate this novel peptide in the regulation of neuroendocrine functions.


Subject(s)
Arcuate Nucleus of Hypothalamus/metabolism , Chromogranins/metabolism , Food Deprivation/physiology , Paraventricular Hypothalamic Nucleus/metabolism , Peptide Fragments/metabolism , Secretogranin II/metabolism , Amino Acid Sequence , Animals , Chromogranins/chemistry , Feeding Behavior/physiology , Female , Immunohistochemistry , Male , Molecular Sequence Data , Peptide Fragments/chemistry , Rodentia , Secretogranin II/chemistry
14.
Ann N Y Acad Sci ; 1040: 137-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15891017

ABSTRACT

Two new amphibian genes have been isolated and characterized from frog melanotropes, and the level of expression of these genes is related to the secretory status of the cells. Both genes, Rab18 and a novel member of the golgin family of proteins, are ubiquitously expressed in endocrine and nonendocrine tissues, and their corresponding proteins appear to show intracellular distributions associated with discrete vesicular and tubular structures, respectively, suggesting that they may play relevant roles in the regulation of the secretory pathway.


Subject(s)
Signal Transduction/physiology , rab GTP-Binding Proteins/metabolism , Animals , Anura , Autoantigens/analysis , Autoantigens/genetics , Biological Transport/physiology , CHO Cells , Cricetinae , PC12 Cells , Rats , rab GTP-Binding Proteins/analysis , rab GTP-Binding Proteins/genetics
15.
J Endocrinol Invest ; 28(10): 949-58, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16419501

ABSTRACT

Regulation of hormone secretion is a complex process that comprises the sequential participation of numerous subcellular mechanisms. Hormone secretion is dictated by extracellular stimuli that are transduced intracellularly into activation/deactivation of different mechanisms, such as hormone expression, processing and exocytosis, which will ultimately determine the precise availability of hormone to be secreted. Malfunction in any of these steps may result in deficient or excessive hormone release and the subsequent appearance of endocrine disorders. Given the complexity of this system, it is difficult to find appropriate cellular models wherein to investigate the multiple components of the secretory process in a physiologically relevant, experimentally manipulable setting. In this review, we present recent evidence on the use of the intermediate lobe (IL) of the pituitary as a powerful tool to understand different aspects of the regulated secretory pathway. IL is composed of a single endocrine cell type, alpha-melanocyte stimulating hormone (alpha-MSH)-producing melanotropes, a fact that greatly facilitates its study. Furthermore, melanotropes can be separated using classic cell separation techniques into two cell subtypes showing opposite morphophysiological phenotypes of hypo- and hypersecretory cells. Comparison of their gene expression fingerprints has unveiled the existence of certain genes preferentially expressed in each melanotrope subtype. Because of their direct participation in the secretory pathway, we postulate that characterization of these gene products in an endocrine cell type may represent novel and useful markers for reliably determining the general secretory status in an endocrine gland, as well as a valuable new tool to further investigate this complex process.


Subject(s)
Pituitary Gland/cytology , Pituitary Gland/metabolism , alpha-MSH/metabolism , Amphibians , Animals , Biomarkers , DNA Fingerprinting , Exocytosis , Gene Expression Regulation , Models, Biological , Phenotype , Pituitary Gland/physiology , alpha-MSH/genetics
19.
J Mol Endocrinol ; 27(2): 229-38, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11564605

ABSTRACT

Recently, a frog pituitary adenylate cyclase-activating polypeptide (PACAP)/vasoactive intestinal peptide (VIP) receptor (fPVR) has been characterized, and interestingly, this receptor exhibits characteristics of both mammalian PACAP type II receptors VPAC(1)R and VPAC(2)R. In order to investigate the receptors responsible for mediating the actions of VIP and PACAP in amphibians, in this report, a frog VPAC(2) receptor (fVPAC(2)R) cDNA was isolated. fVPAC(2)R shares 47.7, 46.9 and 62.5% amino acid sequence identity with fPVR, human VPAC(1)R and human VPAC(2)R respectively. Functionally, fVPAC(2)R, when expressed in CHO cells, was responsive to both frog peptides including VIP, PACAP38 and PACAP27 where the EC(50) values of these peptides in intracellular cAMP production were 0.15, 0.18 and 0.16 microM respectively. The pharmacological profiles of human peptides (VIP, PACAP38 and peptide histidine methionine) to stimulate frog and human VPAC(2)Rs were compared, and it was found that these peptides could only activate the frog receptor at micromolar concentrations. fVPAC(2)R was found to be widely distributed in various peripheral tissues as well as several regions of the brain. The presence of the receptor transcripts suggests the functional roles of the receptor in mediating the actions of PACAP and/or VIP in these tissues. As VIP and particularly PACAP27 are highly conserved peptides in vertebrate evolution, comparative studies of these peptides and their receptors in non-mammalian vertebrates should provide clues to better understand the physiology of these important peptides in human and other vertebrates.


Subject(s)
Pituitary Gland/metabolism , Ranidae/genetics , Ranidae/metabolism , Receptors, Vasoactive Intestinal Peptide/genetics , Receptors, Vasoactive Intestinal Peptide/metabolism , Amino Acid Sequence , Animals , Base Sequence , CHO Cells , Cricetinae , Cyclic AMP/biosynthesis , DNA, Complementary/genetics , DNA, Complementary/isolation & purification , Humans , Molecular Sequence Data , Neuropeptides/metabolism , Phylogeny , Pituitary Adenylate Cyclase-Activating Polypeptide , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Vasoactive Intestinal Peptide/chemistry , Receptors, Vasoactive Intestinal Peptide, Type II , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid , Species Specificity , Tissue Distribution , Vasoactive Intestinal Peptide/metabolism
20.
Microsc Res Tech ; 54(3): 137-57, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11458398

ABSTRACT

Pituitary adenylate cyclase-activating polypeptide (PACAP), a novel peptide of the secretin/glucagon/vasoactive intestinal polypeptide superfamily, has been initially characterized in mammals in 1989 and, only 2 years later, its counterpart has been isolated in amphibians. A number of studies conducted in the frog Rana ridibunda have demonstrated that PACAP is widely distributed in the central nervous system (particularly in the hypothalamus and the median eminence) and in peripheral organs including the adrenal gland. The cDNAs encoding the PACAP precursor and 3 types of PACAP receptors have been cloned in amphibians and their distribution has been determined by in situ hybridization histochemistry. Ontogenetic studies have revealed that PACAP is expressed early in the brain of tadpoles, soon after hatching. In the frog Rana ridibunda, PACAP exerts a large array of biological effects in the brain, pituitary, adrenal gland, and ovary, suggesting that, in amphibians as in mammals, PACAP may act as neurotrophic factor, a neurotransmitter and a neurohormone.


Subject(s)
Adrenal Glands/metabolism , Brain/metabolism , Neuropeptides/metabolism , Rana ridibunda/metabolism , Receptors, Pituitary Hormone/metabolism , Amino Acid Sequence , Animals , Humans , Molecular Sequence Data , Neuropeptides/chemistry , Neuropeptides/genetics , Neuropeptides/isolation & purification , Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
SELECTION OF CITATIONS
SEARCH DETAIL
...